Semaglutide Dosing and Titration Schedule for Clinicians

Last updated: September 2026

Getting semaglutide dosing right is mostly about discipline: start low, escalate on a fixed schedule, and slow down the moment tolerability demands it. The drug is highly effective, but almost every avoidable problem — nausea, vomiting, early discontinuation — comes from pushing the dose faster than the patient’s gut can adapt.

This clinician-focused guide lays out the standard weight-management titration, the higher-dose option the FDA added in 2026, how diabetes dosing differs, when to hold or pause, maintenance targets, product-specific missed-dose handling, and a quick-reference dosing chart you can scan in seconds. It is a practical companion to our complete prescriber’s guide to GLP-1 medications for weight management, which covers selection, safety, and program building in depth.

Key Takeaways

Standard Weight-Management Titration (the Wegovy® Schedule)

For chronic weight management, injectable semaglutide (Wegovy®) follows a fixed five-step escalation, holding each dose for four weeks before moving up. The full ramp to the maintenance dose therefore takes a minimum of 16 weeks.

The schedule is 0.25 mg once weekly for weeks 1–4, then 0.5 mg for weeks 5–8, 1.0 mg for weeks 9–12, 1.7 mg for weeks 13–16, and 2.4 mg once weekly from week 17 onward as the recommended maintenance dose. The 0.25 mg starting dose is deliberately sub-therapeutic — it produces little weight loss and exists purely to let the body adapt and blunt gastrointestinal side effects. Escalating too quickly is the single most common cause of intolerance, so the four-week interval is a floor, not a target to beat.

The 7.2 mg Option: What Changed in 2026

If you learned this schedule before spring 2026, one fact has changed. On March 19, 2026, the FDA approved Wegovy® HD — semaglutide 7.2 mg once weekly — for adults with obesity, and the prescribing information now describes an escalation beyond the long-standing 2.4 mg ceiling.

The labeled condition is specific: for patients who tolerate the 2.4 mg dosage for at least four weeks and in whom additional weight reduction is clinically indicated, the dosage may be increased to a maximum of 7.2 mg once weekly. In the 72-week STEP UP trial that supported the approval, the higher dose produced roughly 20.7% mean weight reduction, with about a third of participants losing a quarter of their body weight or more. Wegovy® HD is supplied as its own single-dose pen rather than as a new setting on the existing device, so a switch means a new prescription, not a dial change.

Two practical caveats. First, 2.4 mg remains the recommended maintenance dose — 7.2 mg is an option for patients who need more, not the new default endpoint of every titration. Second, the higher dose brings the same dose-dependent gastrointestinal profile, so the four-week tolerance requirement is a genuine gate, not a formality. If a patient is still managing nausea at 2.4 mg, the answer is more time at 2.4 mg, not a step up.

Diabetes vs. Obesity Dosing Differences

The same molecule is dosed differently depending on the indication and the product. Semaglutide for type 2 diabetes (Ozempic®) escalates 0.25 mg → 0.5 mg → 1.0 mg → up to a maximum of 2.0 mg once weekly — note there is no 1.7 mg rung and the ceiling is well below Wegovy®’s. Because the two products share an active ingredient, prescribers should be careful not to conflate their schedules or maximum doses. This is the same discipline that applies when you move between agents: the tirzepatide titration schedule runs on entirely different numbers and cannot be reasoned by analogy.

Oral semaglutide adds another wrinkle, and it now comes in two distinct ladders. The diabetes tablet (Rybelsus®) uses a 3 mg → 7 mg → 14 mg once-daily schedule. The weight-management tablet approved in December 2025 — oral Wegovy® — climbs 1.5 mg → 4 mg → 9 mg → 25 mg once daily, holding each step for 30 days and reaching its 25 mg maintenance dose on day 91. Oral semaglutide also carries specific administration rules, so review the practical considerations for prescribing the oral formulation before you switch a patient across routes.

When to Slow, Hold, or Pause Escalation

The written schedule is a default, not a mandate. Titration is a clinical tool, and the prescriber should adjust it to the patient in front of them. The label is unusually direct on this point: if patients do not tolerate a dose during escalation, consider delaying escalation for four weeks.

If a patient is tolerating a dose poorly — persistent nausea, vomiting, or significant GI distress — it is entirely appropriate to hold at the current dose for additional weeks before advancing, or to step back down to the last well-tolerated dose and re-attempt escalation later. Pair that with the practical measures that make a dose survivable in the first place: smaller meals, slower eating, stopping at the first sign of fullness, and the rest of the counseling that keeps GI side effects from ending therapy. The goal is the lowest dose that delivers adequate results while keeping the patient comfortable enough to stay on treatment, because adherence is what ultimately drives weight loss.

Maintenance Dosing and Target Dose

The recommended maintenance dose for injectable semaglutide in weight management is 2.4 mg once weekly, the dose used in the pivotal STEP trials that produced roughly 15% mean weight loss (Wilding et al., 2021). Patients who cannot tolerate 2.4 mg may be maintained at 1.7 mg once weekly rather than discontinued outright — the label names 1.7 mg as an accepted maintenance option, not a failure state. Patients at the other end of the response curve, who tolerate 2.4 mg but have not reached a clinically adequate result, are the group the 7.2 mg dose was approved for. Before escalating either way, it is worth working through why a patient has plateaued, since dose is only one of the explanations.

Maintenance is genuinely long-term. Obesity is a chronic condition, and weight tends to return when the medication is stopped, so the maintenance dose is meant to be continued rather than tapered off once a goal weight is reached. Setting that expectation at the start of treatment prevents disappointment and premature discontinuation later.

Handling Missed Doses and Restarts

Missed doses are common and usually simple to manage — but the rule is product-specific, and this is where clinicians and staff most often give patients the wrong answer. A Wegovy® patient and an Ozempic® patient who each miss a Tuesday injection do not get the same instruction.

Two doses should never be given in the same week to make up a miss. And after a longer gap, tolerability at the previous dose can no longer be assumed — for the injection, reinitiating at a lower dose and re-titrating upward is both what the label directs and the more comfortable path for the patient.

Quick-Reference Semaglutide Dosing Chart

This semaglutide dosing chart summarizes the weight-management titration alongside the diabetes comparison. Always verify against current labeling before prescribing.

Oral semaglutide follows separate schedules: 3 → 7 → 14 mg once daily for diabetes (Rybelsus®), and 1.5 → 4 → 9 → 25 mg once daily — 30 days per step — for weight management (oral Wegovy®). Agent choice sits upstream of all of this; if you are still deciding between molecules, our comparison of tirzepatide versus semaglutide works through the head-to-head evidence.

Frequently Asked Questions

What is the standard semaglutide titration schedule for weight loss?

Injectable semaglutide (Wegovy®) escalates over a minimum of 16 weeks: 0.25 mg once weekly for weeks 1–4, 0.5 mg for weeks 5–8, 1.0 mg for weeks 9–12, 1.7 mg for weeks 13–16, and 2.4 mg once weekly from week 17 as the recommended maintenance dose.

What is the maximum dose of semaglutide?

For weight management the ceiling changed in 2026. The FDA approved Wegovy® HD (semaglutide 7.2 mg once weekly) in March 2026, and the labeling allows an increase to 7.2 mg in patients who have tolerated 2.4 mg for at least 4 weeks and need additional weight reduction. The recommended maintenance dose remains 2.4 mg once weekly. For type 2 diabetes (Ozempic®) the maximum is still 2.0 mg once weekly, and oral Wegovy® for weight management reaches 25 mg once daily.

Why does semaglutide start at such a low dose?

The 0.25 mg starting dose is sub-therapeutic by design. It produces little weight loss and exists only to let the body adapt to the drug’s effect on gastric emptying, minimizing nausea and vomiting before the therapeutic doses begin.

What should a patient do if they miss a weekly dose?

The rule is product-specific, which is a common source of error. For Wegovy® injection, if the next scheduled dose is more than 2 days away the missed dose is given as soon as possible; if it is less than 2 days away the dose is skipped and dosing resumes on the regular day. For Ozempic®, the missed dose can be given within 5 days, after which it is skipped. A missed dose of oral semaglutide is simply skipped and the next dose taken the following day. Never give two doses in the same week.

Can the semaglutide titration schedule be slowed down?

Yes, and the label says so directly: if a patient does not tolerate a dose during escalation, consider delaying escalation for 4 weeks. Holding at the current dose or stepping back to the last tolerated dose is appropriate. Many patients do well below the maximum dose; the best dose is the lowest one that works and is tolerated.

What happens if a patient misses two or more consecutive doses?

For Wegovy® injection the label instructs prescribers to reinitiate dosage escalation at a lower dose to reduce the risk of gastrointestinal adverse reactions. Tolerability at the previous dose can no longer be assumed after a gap, so restarting lower and re-titrating is both the labeled and the more comfortable path.

Do patients stay on semaglutide long-term?

Typically yes. Obesity is chronic and weight tends to return after stopping, so the maintenance dose is intended to be continued rather than tapered once a goal weight is reached. Setting that expectation at the first visit prevents premature discontinuation later.

Conclusion

Semaglutide dosing rewards patience: a fixed four-week escalation to a 2.4 mg weekly maintenance dose for weight management, a lower ceiling for diabetes, a new 7.2 mg option for patients who tolerate 2.4 mg and need more, and the flexibility to slow down whenever tolerability calls for it. Prescribers who respect the titration — and who set long-term expectations early — see fewer dropouts and better results.

To build dosing, titration, and safety protocols with confidence, IAPAM’s GLP-1 certification training for clinicians — backed by more than 20 years of training healthcare professionals and over 6,300 five-star reviews — gives you ready-made clinical frameworks. Clinicians expanding a cash-pay practice often add aesthetic services alongside weight management; the same foundation supports Botox® training for nurse practitioners.

Explore GLP-1 Certification Training →

References

Disclaimer: This article is for informational and educational purposes only and does not constitute medical or prescribing advice. Dosing and labeling change; always verify the current FDA-approved prescribing information for the specific semaglutide product before prescribing.